1. (Once Amended) A residue of a compound of formula I



I

linked to a residue of a molecule comprising B-10, wherein X is CN, OH, CH_3, adenosyl or a molecule comprising B-10; or a pharmaceutically acceptable salt thereof.

25. (Once Amended) A residue of a compound of formula I



I

linked to a group of the formula Q-L-W-Det, wherein X is CN, OH, CH_3, adenosyl, a molecule comprising B-10 or Q-L-W-Det; wherein Det is a chelating group comprising Gd-157; L is a linker or absent; and W and Q are each independently –N(R)C(=O)-, -C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -$S(O)_2$-, -N(R)-, -C(=O)-, or a direct bond; wherein each R is independently H or (C_1-C_6)alkyl; or a pharmaceutically acceptable salt thereof.

31. (Once Amended) A residue of a compound of formula I



I

linked to a residue of a molecule comprising B-10; wherein the residue of the compound of formula I is linked to a group of the formula Q-L-W-Det, wherein X is CN, OH, CH_3, adenosyl, a molecule comprising B-10 or Q-L-W-Det; wherein

1) Det is a chelating group comprising a therapeutic radionuclide or a diagnostic radionuclide;
2) L is a linker or absent; and

Q3

3) Q and W are each independently –N(R)C(=O)-, -C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -S(O)$_2$-, -C(=O)-, -N(R)-, or a direct bond; wherein each R is independently H or (C_1-C_6)alkyl;

or a pharmaceutically acceptable salt thereof.

Q4

45. (Once Amended) The compound of claim 44, wherein the detectable radionuclide is a non-metallic radionuclide.

46. (Once Amended) The compound of claim 45, wherein the non-metallic radionuclide is Carbon-11, Fluorine-18, Bromine-76, Iodine-123 or Iodine-124.

47. (Once Amended) The compound of claim 44, wherein the detectable radionuclide is directly linked to the compound of formula I.

48. (Once Amended) The compound of claim 44, wherein the detectable radionuclide is linked by a linker to the compound of formula I.

49. (Once Amended) The compound of claim 48, wherein the linker is of the formula W-A wherein A is (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, (C_3-C_8)cycloalkyl, or (C_6-C_{10})aryl, wherein W is -N(R)C(=O)-, -C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -S(O)$_2$-, -N(R)-, -C(=O)-, or a direct bond; wherein each R is independently H or (C_1-C_6)alkyl, and wherein A is substituted with one or more non-metallic radionuclides.

65. (Once Amended) A residue of a compound of formula I



I

linked

1) to a molecule comprising B-10 or a chelating group comprising Gd-157; and

2) to at least one residue of the formula Q-L-W-Det, wherein X is CN, OH, CH_3, adenosyl, a molecule comprising B-10 or Q-L-W-Det; wherein each Det is independently a chelating group comprising a metallic radionuclide; each L is

independently a linker or absent; and each W and Q are each independently -N(R)C(=O)-, -C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -S(O)$_2$-, -C(=O)-, -N(R)-, or a direct bond; wherein each R is independently H or (C_1-C_6)alkyl;

or a pharmaceutically acceptable salt thereof.

66. (Once Amended) The compound of claim 1 or 44, wherein the residue of the compound of formula I is also linked to a group comprising Gd-157.

68. (Once Amended) A pharmaceutical composition comprising a compound of any one of claim 1-53 or 65-67 and a pharmaceutically acceptable carrier.

69. (Once Amended) A method of treating a tumor in a mammal in need of such treatment comprising administering to the mammal an effective amount of a compound of any one of claim 1-53 or 65-67 in combination with a pharmaceutically acceptable vehicle; and administering neutron capture therapy.

70. (Once Amended) A method for imaging a tumor in a mammal comprising administering to the mammal a detectable amount of a compound of any one of claim 1-53 or 65-67; and detecting the presence of the compound.

In the Figures

Please amend Figure 1 to be the following: